To "lump" or to "split" in Macrophage Activation Syndrome and Hemophagocytic Lymphohistiocytosis.
The question "To lump or to split?" does not carry the same undertones as Hamlet's searching query but does have far-reaching ramifications for patients and clinicians riding cytokine storms. In this issue, Eloseily et al. report a retrospective analysis of 44 patients with macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH) exposed to the Interleukin (IL)-1 receptor antagonist anakinra at any time in their treatment course. The authors conclude that early use of anakinra may be beneficial in secondary pediatric HLH without an associated malignancy. But with a cohort that includes patients with underlying systemic juvenile idiopathic arthritis (sJIA), malignancy, infection, and at least 10 other potential triggers, should we be lumpers or splitters in applying these data to a given patient? We posit that patients with MAS, other secondary HLH, macrophage activation-like syndrome in sepsis, cytokine release syndrome (CRS) following chimeric antigen receptor T-cell therapy, and other hyperinflammatory syndromes still require individualized approaches to therapy.